• C. REZUS “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Minerva Codruta BADESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi


Direct oral anticoagulants (DOAC) are undeniably a vital pillar of antithrombotic therapy. Dabigatran is a direct thrombin inhibitor that acts by preventing the conversion of fibrinogen to fibrin. Apixaban, betrixaban, edoxaban and rivaroxaban are selective factor Xa inhibitors. Since the first market launch of a DOAC 15 years ago, the number of indications has greatly expanded, based on their superior efficacy and safety in many clinical scenarios compared to classical vitamin K antagonists (VKAs). The indications include prevention of stroke and systemic embolism in patients with atrial fibrillation (AF); prevention of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease; treatment of deep vein thrombosis and pulmonary embolism; prevention of recurrent venous thromboembolism (VTE); and prevention of VTE after total knee or hip replacement, or in hospitalized acutely ill medical patients. DOACs have several advantages over VKA, such as rapid onset and offset of action, limited food and drug interactions and a wider therapeutic window. They have a stable and predictable effect that allows the administration of fixed doses and does not require monitoring of the anticoagulant effect.


1. Chen A, Stecker E, Warden BA. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc 2020; 9: e017559 / doi:10.1161/JAHA.120.017559.
2. Vila Cuenca, M, Hordijk, P.L, Vervloet, M.G. Most exposed: the endothelium in chronic kidney disease. Nephrol Dial Transplant 2020; 35: 1478-1487 / doi:10.1093/ndt/gfz055.
3. Baaten C, Schroer JR, Floege J, et al. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clin J Am Soc Nephrol 2022; 17: 155-170 / doi:10.2215/CJN.04100321.
4. Wu T, Tang LV, Hu Y. Venous Thromboembolism in Kidney Diseases and Genetic Predisposition. Kidney Dis (Basel) 2022; 8: 181-189 / doi:10.1159/000523777.
5. Nayak-Rao S, Shenoy MP. Stroke in Patients with Chronic Kidney Disease: How do we Approach and Manage it? Indian J Nephrol 2017; 27: 167-171 / doi:10.4103/0971-4065.202405.
6. Marenzi G, Cabiati A, Assanelli E. Chronic kidney disease in acute coronary syndromes. World J Nephrol 2012; 1: 134-145 / doi:10.5527/wjn.v1.i5.134.
7. Ocak, G, Lijfering, W.M, Verduijn, M, et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. J Thromb Haemost 2013; 11: 627-633 / doi:10.1111/jth.12141.
8. Rattazzi M, Villalta S, De Lucchi L, et al. Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence. Thromb Res 2017: 160: 32-37 / doi:10.1016/j.thromres.2017.10.011.
9. Wang IK, Shen, TC, Muo CH, Yen TH, Sung FC. Risk of pulmonary embolism in patients with end-stage renal disease receiving long-term dialysis. Nephrol Dial Transplant 2017; 32: 1386-1393 / doi:10.1093/ ndt/gfw272.
10. Molnar AO, Bota SE, Garg AX, et al. The Risk of Major Hemorrhage with CKD. J Am Soc Nephrol 2016; 27: 2825-2832 / doi:10.1681/ASN.2015050535.
11. Kimachi, M, Furukawa, T.A, Kimachi, K, Goto, Y, Fukuma, S, Fukuhara, S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev 2017, 11, CD011373, doi:10.1002/ 14651858. CD 011373.pub2.
12. Rogula S, Gasecka A, Mazurek T, Navarese EP, Szarpak L, Filipiak KJ. Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease. Int J Environ Res Public Health 2022; 19: 1436 / doi:10.3390/ijerph19031436.
13. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498 / doi:10.1093/eurheartj/ehaa612.
14. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131: 972-979 / doi:10.1161/ CIRCU-LATIONAHA.114.014113.
15. Davis E, Darais D, Fuji K, Nekola P, Bashir K. Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. Pharmacy (Basel) 2020; 8(1): 37 / doi:10.3390/pharmacy8010037.
16. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138: 1519-1529 / doi:10.1161/CIRCULATIONAHA.118.035418.
17. Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation 2022; 146: 1735-1745 / doi:10.1161/ CIRCULATIONAHA.121.054990.
18. Alhousani, M, Malik, S.U, Abu-Hashyeh A, et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis. Thromb Res 2021; 198: 103-114 / doi:10.1016/j.thromres.2020.11.036.
19. Cheung CYS, Parikh J, Farrell A, Lefebvre M, Summa-Sorgini C, Battistella M. Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes. Ann Pharmacother 2021; 55: 711-722 / doi:10.1177/ 10600 28020967635.
20. Ellenbogen MI, Ardeshirrouhanifard S, Segal JB, Streiff MB, Deitelzweig SB, Brotman DJ. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study. J Hosp Med 2022; 17: 809-818 / doi:10.1002/jhm.12926.
21. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992 / doi:10.1056/NEJMoa1107039.
22. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 / doi:10.1056/NEJMoa0905561.
23. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104 / doi:10.1056/NEJMoa1310907.
24. Patel, M.R, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891 / doi:10.1056/NEJMoa1009638.
25. Rohla M, Pecen L, Cemin R, et al. Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circ Cardiovasc Qual Outcomes 2021; 14: e006852 / doi:10.1161/ CIRCOUTCOMES.120.006852.